Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12DEH | ISIN: CH0256379097 | Ticker-Symbol: 6ML
Lang & Schwarz
07.11.24
21:19 Uhr
5,525 Euro
-0,410
-6,91 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MOLECULAR PARTNERS AG Chart 1 Jahr
5-Tage-Chart
MOLECULAR PARTNERS AG 5-Tage-Chart
RealtimeGeldBriefZeit
5,4705,58021:19

Aktuelle News zur MOLECULAR PARTNERS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiMolecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition196Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic and pharmacodynamic activity Switch-DARPin...
► Artikel lesen
31.10.Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going236Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected...
► Artikel lesen
31.10.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer5
25.10.Molecular Partners legt Preis für Aktienangebot in den USA fest4
25.10.Molecular Partners gibt ADS im Wert von 20 Millionen Dollar aus - HBM Healthcare neuer Investor16
25.10.Molecular Partners prices $20M offering1
25.10.Molecular Partners Announces Pricing of $20 Million Underwritten Offering242ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics...
► Artikel lesen
22.10.Molecular Partners stock climbs 6% on expanded radiopharmaceuticals deal3
22.10.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
22.10.Molecular Partners und Orano stärken Partnerschaft23
22.10.Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics264Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each)Molecular Partners will hold...
► Artikel lesen
22.10.Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024265Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision...
► Artikel lesen
07.10.Molecular Partners-Aktien steigen nach Outperform-Bewertung von Leerink24
04.10.Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting310Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40)...
► Artikel lesen
27.09.Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024377First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN...
► Artikel lesen
27.08.Molecular Partners rethinks tetra-specific dosing after seeing 'suboptimal exposure' in cancer trial12
27.08.Molecular Partners berichtet über starke Finanzlage9
26.08.Molecular Partners reports 1H results3
26.08.Molecular Partners Reports H1 2024 Corporate Highlights and Financials291First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with...
► Artikel lesen
26.08.MOLECULAR PARTNERS AG - 6-K, Report of foreign issuer3
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4